Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen Inc (AMGN) reports a 9% revenue increase and advances its diverse portfolio with significant sales growth across key ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Explore Amgen's Q2 2025 earnings insights, showcasing 9% revenue growth, robust product performance, and innovation in obesity, rare disease, and ...

In a report released today, from Oppenheimer maintained a Buy rating on Amgen, with a price target of $380.00. The company’s shares closed yesterday at $300.08. Elevate Your Inv ...

Truist Financial analyst Srikripa Devarakonda maintained a Hold rating on Amgen today. The company’s shares closed yesterday at $300.08. Elevate Your Investing Strategy: Take ad ...

The Thousand Oaks, California-based company said it had net income of $2.65 per share. Earnings, adjusted for non-recurring costs, came to $6.02 per share. The results topped Wall Street expectations.